TrialGynecologic oncology2018

Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

Robert A Burger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.